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Abstract
The BRAFV600E mutation is specific for thyroid papillary cancer (PTC) and correlates with PTCs 
invasiveness. This study investigated whether detection of BRAFV600E mutation can be performed 
on routinely stained FNABs. We also examined if establishment of the BRAFV600E mutation could 
help in identification of patients at higher risk for metastatic disease. DNA was isolated from 134 
FNABs samples (20 follicular neoplasm, ten suspicious for malignancy, and 104 malignant) using 
Pinpoint Slide DNA Isolation System. BRAFV600E mutation was detected by PCR followed by 
sequencing. DNA was successfully extracted from all examined FNABs samples. In follicular 
neoplasm, suspicious for malignancy and malignant FNABs, BRAFV600E mutation was found in 
0/20 (0%), 2/10 (20%), and 47/104 (45.2%) of cases, respectively. Extra-thyroidal extension was 
detected in 35/47 (74.4%) BRAFV600E positive and in 24/57 (42.1%) wild-type BRAF cases 
(p=0.001). Metastases were detected in 37/47 (78.7%) BRAFV600E positive and in 28/57 (49.1%) 
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wild-type BRAF cases (p=0.002). Our results showed that stained FNAB specimens can be used 
for DNA extraction and assessment of BRAFV600E mutation. Detection of BRAFV600E mutation 
had limited value in diagnoses of malignancy in follicular neoplasms but can ascertain malignancy 
in subset of suspicious for malignancy FNABs. In malignant FNABs, BRAFV600E mutation was 
significantly associated with presence of extra-thyroidal extension and metastases after surgery.
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Introduction
Papillary thyroid cancer (PTC) is the most common thyroid cancer, accounting for 80% or 
more of all thyroid cancers [1]. The majority of patients with PTC are effectively treated 
with thyroidectomy and postoperative I131 therapy, but up to 20% of thyroid cancer patients 
develop persistent/recurrent disease which is associated with increased morbidity and 
mortality.
The extent of initial surgery for PTC has a significant impact on disease recurrence [2, 3]. It 
is generally agreed that therapeutic neck dissection should be performed to remove 
macroscopic lymph node metastases, in order to reduce the likelihood of persistent/recurrent 
PTC. Whether routine prophylactic central neck dissection warrants the greater risk of 
complications remains debatable. These controversies are due to the imprecision in the risk 
estimation of thyroid cancer aggressiveness based on clinical information and the available 
preoperative testing.
Fine-needle aspiration biopsy (FNAB) is currently considered the most effective technique 
for morphological diagnosis of thyroid nodules [4, 5]. The Bethesda System for Reporting 
Thyroid Cytopathology has provided a diagnostic terminology including benign (B), atypia 
of undetermined significance (AUS), follicular neoplasm (FN), suspicious for malignancy 
(SM), malignancy (M), and non-diagnostic (ND) for the interpretation of FNAB. The meta 
review analysis showed that risk of malignancy in diagnostic categories B, AUS, FN, SM, M 
and ND was 6%, 16%, 25%, 62%, 97%, and 12%, respectively [6]. Patients with follicular 
neoplasm, suspicious for malignancy, and malignant FNABs are commonly referred for 
surgery. However, preoperative FNAB cannot always accurately guide the extent of optimal 
surgical intervention.
With malignant cytologic findings on FNAB, a preoperative neck ultrasound is 
recommended to examine the cervical lymph nodes in all patients undergoing thyroidectomy 
[7]. Preoperative ultrasound can identify suspicious cervical adenopathy in 20–31% of cases, 
potentially altering the surgical approach in this group of patients [8, 9]. Preoperative 
ultrasound, however, will only identify 50% of the lymph nodes found at surgery, due to the 
presence of the overlying thyroid gland [10]. Clearly, there is a necessity for additional 
preoperative risk stratification tools, such as the detection of molecular characteristics 
associated with more aggressive tumors.
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BRAF mutations are common in human cancers, with a prevalence of up to 66–83% in 
melanoma and thyroid cancer [11]. The oncogenic BRAFV600E mutation has been widely 
found in PTC, as well as in some anaplastic thyroid cancers, with prevalence in PTC of 
approximately 45%. Previous studies have established an association between BRAF 
mutations and aggressive clinicopathologic characteristics of primary PTC, including extra-
thyroidal extension, lymph node metastasis, histologic subtypes with a poorer prognosis, and 
advanced disease stages [12, 13]. Recent data have demonstrated that BRAF mutation 
testing of FNAB samples provides a novel tool to the preoperative identification of PTC 
patients at higher risk for extensive disease [14].
The aim of this study was to determine whether routinely stained FNAB specimens could be 
used for DNA extraction and assessment of the BRAFV600E mutation. We sought to 
establish whether detection of BRAFV600E mutation could improve the cytologic diagnosis 
in cases of follicular neoplasm and suspicious for malignancy FNABs. We also investigated 
whether establishment of BRAFV600E mutation in malignant FNABs could help in the 
preoperative identification of patients at higher risk for metastatic disease.
Material and Methods
Thyroid Tissue Samples
Thyroid tissue samples were obtained in accordance with protocols approved by the Human 
Use Committee at The Center for Endocrine Surgery, Kiev, Ukraine, and maintained in an 
archival bank approved by the Uniformed Services University of the Health Sciences, 
Bethesda, MD. FNAB specimens from 134 patients were examined. All FNAB specimens 
were stained by the May-Grünwald Giemsa (MGG) technique. The cytological diagnoses 
consisted of three categories that indicate surgery: follicular neoplasm (20 cases), suspicious 
for malignancy (ten cases), and malignant (104 cases). All patients were treated at the Center 
for Endocrine Surgery and underwent thyroidectomy in the Department of Surgery. The 
initial treatment was total thyroidectomy and, when necessary, central neck and/or 
laterocervical lymph node dissection. Histological diagnoses were made independently, in a 
blinded fashion, by two pathologists (V.H. and V.V.) and tumors were classified according to 
the histopathological typing of the World Health Organization.
Comparison of FNAB diagnoses to the final histology showed that among follicular 
neoplasms there were four follicular adenomas (FA), five Hürthle cell adenomas, four 
follicular carcinomas (FC), and seven follicular variant of papillary carcinomas (FVPC). In 
suspicious for malignancy FNABs there were one FA, one FC, three FVPC, and five PTCs. 
All malignant FNABs were classified as malignant tumors on histology and included 11 
FVPC and 93 classical PTCs.
DNA Extraction and Detection of BRAF Mutation
DNA was extracted from routinely prepared FNAB samples with a proprietary DNA 
extraction kit (Zymo Research, Irvine, CA) according to the manufacturer’s procedure. In 
brief, the samples were covered with the “pinpoint solution,” air-dried and scraped with a 
blade into a tube. Extraction buffer and proteinase K were added, and samples were 
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incubated at 55°C for 4 h and at 98°C for 10 min. DNA was eluted using the DNA Clean 
and Concentrator-5 kit (Zymo Research, Irvine, CA) according to the manufacturer’s 
instructions.
Amplification of the BRAF gene, exon 15, was performed using 20 ng of DNA, 12.5 μL of 
GoTaq Hot Start Mastermix (Promega, Madison, WI), 10 pM of forward primer 5′-
TCATAATGCTTGCTCTGATAGGA-3′, 100 nM of reverse primer 5′-
GGCCAAAAATTTAATCAGTGGA-3′, and DNase/RNase-free water up to a final volume 
of 22 μL. Conventional PCR amplification protocol was composed of an initial activating 
step at 94°C for 15 min, a cycling step (40 cycles) performed as follows: 94°C for 30 s, 58°C 
for 1 min, 72°C for 30 s, and of a final extension at 72°C for 10 min. The PCR product was 
subjected to the restriction endonuclease TspR1 (New England BioLabs, Ipswich, MA) 
treatment. In brief, 7 μL of the PCR product was incubated with 1 μL of TspRl, 1 μL of 
NEbuffer 4 and BSA (New England Biolabs, Ipswich, MA) at 65°C for 2 h.
The denatured PCR products were electrophoresed in a 2% agarose gel (Invitrogen, 
Carlsbad, CA). Digestion of the 237-base pair (bp) PCR fragment with restriction 
endonuclease TspRl yielded two major bands of 117 and 87 bp for the wild-type allele. The 
BRAFV600E mutation abolished the restriction sites, resulting in a prominent band of 237 bp 
from the mutant allele and residual bands from the normal allele.
To confirm the results, direct sequencing was performed for selected samples. The amplified 
products were purified with a QIAGEN PCR purification kit and sequenced using the 
forward primer described previously with Big Dye Terminator (ABI Systems, Applied 
Biosystems, Foster City, CA) and an ABI PRISM 3100 Avant Genetic Analyzer (Perkin-
Elmer, Waltham, MA).
Statistical Analysis
Data were analyzed using SPSS software and p<0.05 denoted the presence of a significant 
difference.
Results
Evaluation of Sample Adequacy for Molecular Testing
To determine whether detection of BRAFV600E mutation can be an adjunct technique to 
standard cytological examination, we extracted DNA from FNAB samples that already had 
been stained by the MGG technique and were subsequently used for routine cytological 
analysis. This approach was helpful for the identification of highly cellular slides and 
localization of areas of interest for DNA extraction. The quantity of DNA was assessed 
before molecular testing and ranged from 1 μg to 10 μg. The quality of DNA was assessed 
by PCR amplification of the BRAF gene. All examined FNAB samples demonstrated 
satisfactory DNA quality with a PCR amplification cycle threshold less than 35 cycles.
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Detection of BRAFV600E Mutation in Follicular Neoplasms and Suspicious for Malignancy 
FNABs Samples
To determine whether detection ofBRAFV600E mutation could improve diagnostic accuracy 
of FNABs, we examined the BRAFV600E mutation status on preoperative FNAB specimens 
from follicular neoplasm (20 cases) and suspicious for malignancy lesions (ten cases). The 
results of BRAF mutation status as a function of histology are summarized in Table 1.
In the group of follicular neoplasm, BRAFV600E mutation was not found in any of examined 
cases. In suspicious for malignancy FNABs, BRAFV600E mutation was found in two of ten 
cases (one FVPC and in one PTC).
Detection of BRAFV600E Mutation in Malignant FNABs
We examined the BRAFV600E mutation status on preoperative FNAB specimens from 104 
PTC patients and assessed the relationship to clinicopathologic characteristics of these 
patients. BRAFV600E mutation was found in 43 of 93 (46.2%) conventional PTC patients 
and in four of 11 (36.3%) follicular variant PTC patients, with an overall prevalence of 
45.2%.
By univariate analysis of our data set, no significant statistical correlation was found 
between BRAFV600E and patient’s age or gender (see Table 2). The frequency of 
BRAFV600E mutation was not significantly different between patients who were younger 
than 45 years and patients whose age was 45 years and older at the time of surgery.
The incidence of BRAFV600E mutation has also been examined in function of pathological 
parameters such as tumor size, multifocality, extra-thyroidal invasion, and presence of nodal 
metastases. In this series of samples, no significant association was found between tumor 
size and BRAF mutation status. Results demonstrating association between BRAFV600E 
mutation and pathological characteristic of thyroid tumors are summarized in Table 3. 
Multifocal growth was more frequently detected in BRAFV600E-positive than in mutation-
negative PTCs, but the difference was not statistically significant. There was a significant 
association of BRAFV600E mutation in preoperative FNAB specimens with the presence of 
extra-thyroidal extension and lymph node metastases after histological examination of 
postoperative tissue samples.
Discussion
Fine-needle aspiration biopsy is an effective method for preoperative evaluation of thyroid 
nodules. Molecular methods such as mutation detection or expression profile analysis are 
promising tools to improve the diagnostic accuracy of FNABs. The efficacy of molecular 
testing largely depends on quality and quantity of isolated nucleic acids from FNAB 
samples. The collection of cytological material for molecular testing requires supplementary 
steps during FNAB procedure to include additional aspiration of nodules, needle washout 
with nucleic acids preserving solution and storage of FNABs samples at low temperature. In 
this current study, we initially sought to determine whether routinely stained FNAB 
specimens can be used for DNA extraction. Our results demonstrated that initial cytological 
examination of stained samples is useful in determining areas of high cellular density for 
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further DNA extraction. After identification of the extraction site, DNA was successfully 
isolated from routinely stained FNAB samples, and the quality of the DNA isolated from 
stained samples was sufficient for genetic analysis. In our study, the amount of isolated DNA 
was higher compared to previously reported data, when nucleic acids were isolated from 
material obtained from FNAB needle washout [15, 16].
Molecular evidence has demonstrated associations between BRAF mutations and thyroid 
cancer. Experimental studies, including transgenic mouse models, have shown ability of the 
BRAFV600E mutation to promote aggressiveness and progression of PTC [11, 17]. Previous 
studies suggested that identification of a BRAFV600E mutation in thyroid aspirates could 
help distinguish between benign and malignant tumors when the cytologic examination is 
inconclusive [15]. Several multivariate analyses have demonstrated that the presence of 
BRAFV600E mutation in PTC is an independent risk factor for disease persistence/recurrence 
[11, 18, 19].
We examined BRAFV600E mutation status in a series of FNABs that were classified as 
follicular neoplasm or suspicious for malignancy. For patients with these cytological 
diagnoses, the ATA guidelines recommend either thyroid lobectomy or total thyroidectomy. 
We sought to establish whether detection of BRAFV600E mutation could ascertain the 
diagnosis and guide the extent of surgery in these cases. In patients with follicular neoplasm, 
BRAFV600E mutation was not detected in any samples, including 11 histologically 
confirmed thyroid cancers. These results suggest that detection of BRAFV600E mutation has 
a limited value in patients with FNAB diagnoses follicular neoplasm. In suspicious for 
malignancy FNABs, we detected BRAFV600E mutation in two of ten examined cases. Two 
of seven histologically confirmed cancers in this category were BRAF positive. These results 
suggest that detection of BRAFV600E mutation may be helpful to ascertain a diagnoses of 
cancer in subset of patients with suspicious for malignancy FNABs.
In the current study, the BRAFV600E mutation was detected in 45% of malignant FNABs. 
These results are comparable with previously published data on prevalence of the 
BRAFV600E mutation in papillary thyroid cancers. Numerous studies from patients of 
various ethnic and geographic backgrounds have demonstrated an association between the 
BRAFV600E mutation with aggressive clinicopathologic characteristics of PTCs such as 
extathyroidal extension and lymph nodes metastases [12, 13, 19]. Our study also showed 
that BRAFV600E mutation in malignant FNAB was significantly associated with the 
presence of extra-thyroidal invasion and lymph node metastases. It has to be noted that 
lymph node metastases were detected in 49.1% of BRAFV600E-negative PTCs. These results 
are consistent with previously reported data showing the presence of metastases in 44% of 
BRAFV600E-negative PTCs [20].
Together, these data indicate that detection of a BRAF mutation in malignant FNAB samples 
is a promising tool for evaluation of PTC aggressiveness, however, absence of BRAF 
mutation in malignant FNABs does not rule out the possibility of lymph nodes metastases. 
Additional studies are needed to determine whether detection of a BRAF mutation will have 
greater predictive value for the predicting the presence of lymph node metastases compared 
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to preoperative neck ultrasound. This could be important for selection of appropriate surgery 
in patients with malignant FNABs results but with negative preoperative neck ultrasound.
We detected BRAFV600E mutation in five of 21 (23.8%) histologically confirmed FVPC. A 
BRAFV600E mutation was present in 0% of follicular lesions, 33.3% of lesions suspicious 
for malignancy and 36.3% of lesions with malignant cytology. Our data are similar to results 
from a study examining BRAF mutation status in 187 FVPC in function of cytological 
diagnoses [21]. In this study, a BRAFV600E mutation was detected in 11% of FVPC 
diagnosed as follicular neoplasm, in 27.6% of FVPC diagnosed as suspicious for carcinoma 
and in 54.5% of FVPC diagnosed as malignant by FNABs. These results show that FVPC 
diagnosed as malignant on standard FNAB more frequently harbor BRAF mutation 
compared with the FVPC falling into the follicular neoplasm cytological group.
In conclusion, we have demonstrated that stained FNAB specimens can be used for DNA 
extraction and assessment of the BRAFV600E mutation. Detection of the BRAFV600B 
mutation has limited value in establishing a malignant diagnosis in follicular neoplasm but 
can ascertain diagnoses in subset of patients with FNAB suspicious for malignancy. In 
malignant FNABs, BRAFV600E mutation is associated with risk of extra-thyroidal extension 
and metastases; however, further studies are needed to determine the cohort of thyroid 
cancer patients that would benefit from preoperative testing.
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Table 1
Detection of BRAF mutation in indeterminate FNABs
Histology Follicular neoplasm (20) Suspicious for carcinoma (10)
BRAF (+) BRAF (−) BRAF (+) BRAF (−)
FA (10) 0 9 0 1
FC (5) 0 4 0 1
FVPC (10) 0 7 1 2
PTC (5) 0 0 1 4
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Table 2
Association of BRAF mutation with demographic characteristics of patients
BRAF positive (47 cases) BRAF negative (57 cases) p value
Age at diagnosis (year)
 Mean/standard deviation 42.4/13.3 40.3/17.3 0.49
Gender
 Male/female 8/39 13/44 0.62
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Table 3
Association of BRAF mutation with pathologic characteristics of tumors
BRAF positive (47 cases) BRAF negative (57 cases) p value
Multifocality (yes) 21 (44.6%) 16 (28.1%) 0.1
Extra-thyroidal extension (yes) 35 (74.4%) 24 (42.1%) 0.001
Lymph node metastases (yes) 37 (78.7%) 28 (49.1%) 0.002
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